Meng Wang, W H Wilson Tang, Xinmin S Li, Marcia C de Oliveira Otto, Yujin Lee, Rozenn N Lemaitre, Amanda Fretts, Ina Nemet, Nona Sotoodehnia, Colleen M Sitlani, Matthew Budoff, Joseph A DiDonato, Zeneng Wang, Nisha Bansal, Michael G Shlipak, Bruce M Psaty, David S Siscovick, Mark J Sarnak, Dariush Mozaffarian, Stanley L Hazen
BACKGROUND: Trimethylamine N-oxide (TMAO) is a gut microbiota-derived metabolite of dietary phosphatidylcholine and carnitine. Experimentally, TMAO causes kidney injury and tubulointerstitial fibrosis. Little is known about prospective associations between TMAO and kidney outcomes, especially incident CKD. We hypothesized that higher plasma TMAO levels would be associated with higher risk of incident CKD and greater rate of kidney function decline. METHODS: We included 10,564 participants from two community-based, prospective cohorts with estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1...
April 9, 2024: Journal of the American Society of Nephrology: JASN